Showing results (271-280 of 9,098) with videos related to
Sort By:
Pageof 910
Cancer Medicine|September 20, 2019
Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health AdministrationSherrie L Aspinall, Xinhua Zhao, Mark C Geraci, et al.Cancer Medicine|August 23, 2019
The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysisBi-Cheng Wang, Ru-Bo Cao, Pin-Dong Li, et al.Cancer Medicine|October 2, 2019
SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathwayJilin Xing, Ji Li, Lin Fu, et al.Cancer Medicine|October 2, 2019
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trialFrancisco-Javier Peñalver, José-Antonio Márquez, Soledad Durán, et al.Cancer Medicine|March 2, 2019
A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in GermanyMiriam Reuschenbach, Ingeborg Tinhofer, Claus Wittekindt, et al.Cancer Medicine|March 2, 2019
Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patientsChristian F Singer, Yen Y Tan, Daniela Muhr, et al.Cancer Medicine|February 16, 2019
The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome predictionJunjie Hang, Junjie Huang, Siyuan Zhou, et al.Cancer Medicine|November 16, 2018
DSCAM-AS1 regulates the G1 /S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapyWei Sun, An-Qi Li, Ping Zhou, et al.Cancer Medicine|November 17, 2018
Elevated EGFL6 modulates cell metastasis and growth via AKT pathway in nasopharyngeal carcinomaZiyu Zhu, Haosheng Ni, Bo You, et al.Cancer Medicine|February 22, 2019
Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphomaHajime Senjo, Minoru Kanaya, Koh Izumiyama, et al.Pageof 910